Indication intelligence, analysis and sector perception

Aduro Biotech (ADRO): US PTO issued two patents

January 5, 2016 10:23am

Covering composition and methods related to its LADD and GVAX immunotherapy technologies

Patents issued:

Patent 9,198,960 claims methods for enhancing an immune response to mesothelin by administering first a "prime" dose of an inactivated tumor cell containing a nucleic acid that encodes granulocyte macrophage-colony stimulation factor (GM-CSF) followed by a "boost" dose of an immunotherapy. The nominal expiration date for this patent is July 17, 2027, subject to any extensions that may be available.

Patent 9,200,057, which is jointly owned with Providence Health & Services. The nominal expiration date for this patent is November 17, 2031, subject to any extensions that may be available.

The Bottom Line: These two patents expand its claims associated with therapeutic approaches and extend patent coverage into 2031

ADRO is UP +$0.15 on small volume to $26.79

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.